#1 Clinical Trials Search in Europe

Human Papillomavirus Type 6 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus Type 6 L1 Protein as part of the 9-valent HPV vaccine (9vHPV or Gardasil 9) for preventing HPV infections and related diseases. The trials examine the vaccine’s safety, immunogenicity, and efficacy in various populations and dosing regimens, including extended dosing intervals in young people, use in immunocompromised patients, and potential therapeutic applications for existing HPV-related conditions.

Table of Contents

What is Human Papillomavirus Type 6 (HPV6)?

Human Papillomavirus Type 6 (HPV6) is a specific strain of the human papillomavirus. HPV is a common virus that can infect various parts of the body, including the genital areas, mouth, and throat. HPV6 is known as a low-risk type, meaning it rarely causes cancer. However, it is one of the main causes of genital warts.[1]

About the HPV6 L1 Protein Vaccine

The HPV6 L1 Protein vaccine is a component of a larger vaccine called Gardasil 9. This vaccine is designed to protect against nine different types of HPV, including HPV6. The “L1 Protein” refers to the main protein that makes up the outer shell of the virus. By using this protein in the vaccine, the body can learn to recognize and fight off the actual virus if exposed.[1]

How the Vaccine Works

The vaccine works by introducing a harmless version of the HPV6 L1 protein into the body. This protein is produced in yeast cells using recombinant DNA technology, which means scientists have engineered the yeast cells to produce the viral protein. When injected, these proteins form virus-like particles that mimic the structure of the real virus but cannot cause infection. This triggers an immune response, teaching the body to recognize and fight off the actual virus if encountered in the future.[1]

Medical Conditions Treated or Prevented

The HPV6 L1 protein vaccine, as part of Gardasil 9, helps prevent several conditions:

  • Genital warts caused by HPV6 and HPV11
  • Persistent anogenital HPV infection
  • Cervical, vulvar, vaginal, and anal precancerous lesions
  • Cervical, vulvar, vaginal, and anal cancers caused by HPV types included in the vaccine

While HPV6 itself is not a cancer-causing type, the vaccine protects against other high-risk HPV types that can lead to cancer.[1][2]

Vaccine Administration

The vaccine is typically administered as a series of injections:

  • For individuals 9-14 years old: 2 doses, with the second dose given 6-12 months after the first
  • For individuals 15 years and older: 3 doses, with the second dose given 2 months after the first, and the third dose given 6 months after the first

The vaccine is given as an intramuscular injection, usually in the upper arm or thigh.[1][1]

Effectiveness and Immune Response

Studies have shown that the vaccine is highly effective in preventing HPV6-related infections and conditions when given before exposure to the virus. The vaccine stimulates the production of antibodies against HPV6, providing long-lasting protection. Research indicates that the vaccine can induce a strong immune response, with high levels of antibodies persisting for several years after vaccination.[1][3]

Safety and Side Effects

The HPV6 L1 protein vaccine has been extensively tested and is considered safe. Common side effects may include:

  • Pain, redness, or swelling at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious side effects are rare but can include severe allergic reactions. It’s important to discuss any concerns or medical conditions with your healthcare provider before receiving the vaccine.[1][2]

Ongoing Research and Future Directions

Current research is exploring various aspects of the HPV6 L1 protein vaccine, including:

  • Extended dosing intervals to potentially reduce the number of required doses
  • Effectiveness in immunocompromised populations
  • Use in preventing oral HPV infections and related cancers
  • Potential therapeutic effects in treating existing HPV-related conditions

These studies aim to optimize vaccine use, expand its applications, and improve protection against HPV-related diseases.[1][3][4]

Trial Focus Population Key Objectives Dosing Regimen
Extended dosing intervals Boys and girls 9-14 years, women 16-26 years Compare immunogenicity of 2-dose vs 3-dose regimens 2-dose with 12-60 month intervals vs standard 3-dose
Immunocompromised patients Children and adolescents 9-18 years post-transplant Evaluate immunogenicity in immunocompromised individuals 3-dose regimen starting at 9 or 15 months post-transplant
Oral HPV prevention Adult males 20-45 years Assess efficacy in preventing oral HPV infections 3-dose regimen
Vulvar HSIL treatment Women with vulvar HSIL Evaluate efficacy in preventing HSIL recurrence 3-dose regimen as adjuvant therapy
Cervical lesion treatment Women over 45 with high-grade cervical lesions Assess HPV clearance after treatment and vaccination 3-dose regimen
Palmar/plantar wart treatment Patients ≥15 years with difficult-to-treat warts Evaluate efficacy in treating resistant warts 3-dose regimen

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine (9vHPV or Gardasil 9) is a vaccine that protects against nine types of human papillomavirus (HPV), including types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It contains virus-like particles of the L1 protein from each of these HPV types.
  • Who is being studied in these clinical trials? The clinical trials involve various populations, including children and adolescents aged 9-14, young adults aged 16-26, immunocompromised patients, women with vulvar high-grade squamous intraepithelial lesions (vHSIL), and adult males aged 20-45.
  • What are some of the main objectives of these trials? The trials aim to evaluate the safety, immunogenicity, and efficacy of the 9vHPV vaccine in different populations, assess extended dosing intervals, study its use in immunocompromised patients, investigate its potential in treating existing HPV-related conditions, and examine its effectiveness in preventing oral HPV infections.
  • How is the vaccine administered in these trials? The vaccine is typically administered as a series of intramuscular injections. Some trials are studying different dosing schedules, such as 2-dose regimens with extended intervals between doses, while others follow the standard 3-dose regimen.
  • What are some of the outcomes being measured in these trials? The trials measure various outcomes, including antibody responses to HPV types, seroconversion rates, incidence of HPV infections, clearance of existing HPV infections, quality of life improvements, and safety indicators such as adverse events following vaccination.

Ongoing Clinical Trials on Human Papillomavirus Type 6 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • HPV: Human Papillomavirus, a group of viruses that can cause various types of cancer and genital warts.
  • 9vHPV: 9-valent Human Papillomavirus Vaccine, also known as Gardasil 9, which protects against nine types of HPV.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent.
  • GMT: Geometric Mean Titer, a measure of the average antibody levels in a group of subjects.
  • cLIA: Competitive Luminex Immunoassay, a method used to measure antibody levels.
  • HSIL: High-grade Squamous Intraepithelial Lesion, a precancerous condition that can occur in the cervix or vulva.
  • Allogeneic stem cell transplantation: A procedure where a person receives blood-forming stem cells from a genetically similar, but not identical, donor.
  • Immunocompromised: Having a weakened immune system, which can be due to certain diseases or medical treatments.
  • Persistent infection: An infection that remains in the body for an extended period, often without causing immediate symptoms.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-for-women-with-vulvar-hsil-evaluating-the-effectiveness-of-nonavalent-hpv-vaccine-in-preventing-recurrence-of-vulvar-high-grade-lesions/